Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Targeted Treatment of Oral and Maxillofacial Diseases
share announcement

Targeted Treatment of Oral and Maxillofacial Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dentistry, Oral Surgery and Oral Medicine".

Deadline for manuscript submissions: closed (10 July 2023) | Viewed by 7109

Special Issue Editors

Dr. Lin-Lin Bu

E-Mail Website
Guest Editor
Department of Oral Maxillofacial Head Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan, 430079, China
Interests: complicated head neck oncology; head & neck reconstruction surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Cheng Wang

E-Mail Website
Guest Editor
Hospital of Stomatology, Sun Yat-sen University, Guangzhou 510055, China
Interests: head and neck oncology
Dr. Wenbo Zhang

E-Mail Website
Guest Editor
Peking University Hospital of Stomatology, Beijing, China
Interests: oral and maxillofacial oncology and reconstruction
Dr. Jiannan Liu

E-Mail Website
Guest Editor
Department of Oral & Maxillofacial- Head & Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Interests: complicated head neck oncology; head & neck reconstruction surgery especially in jaw reconstruction; robot surgery

Special Issue Information

Dear Colleagues,

Oral and maxillofacial diseases represent a major health burden for many countries, and affect people throughout their lifetime, causing pain, discomfort, disfigurement, and even death. An in-depth understanding of the pathogenesis, diagnosis, and treatment of different oral diseases is vitally important for the maintenance of public oral health. Targeted therapy is a hot topic in the research of disease treatment strategies. The advantage of targeted therapy is that it can accurately focus the disease site, thus reducing the side effects brought by treatment. The introduction of targeted therapy into oral and maxillofacial diseases is also a hot issue in the field of oral science.

Odontogenic tumors are a group of lesions that originate from remnants of epithelium or ectomesenchyme associated with tooth development. Genetic studies have revealed certain gene mutations (BRAF, PTCH1, etc.) in odontogenic tumors. Recently, clinical studies using targeted therapy have attracted broad attention in this field. In addition, immunotherapy involves the stimulation of specific components of the immune system, thereby strengthening anti-tumor effects. Recent research has introduced immunotherapy as an effective treatment option for oral cancers.

This Special Issue will be entitled "Targeted Treatment of Oral and Maxillofacial Diseases", and will focus on the treatment mechanisms and new targeted treatment strategies for the targeted treatment of oral and maxillofacial diseases. Authors are welcome to share experimental papers and review articles presenting the state of the art and new data.

Dr. Lin-Lin Bu
Dr. Cheng Wang
Dr. Wenbo Zhang
Dr. Jiannan Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oral and maxillofacial diseases
  • targeted therapy
  • therapeutic mechanism
  • immunotherapy
  • treatment strategy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1959 KiB  
Article
Comparison of Definitive Radiotherapy-Based Treatment and Surgical-Based Treatment for Locally Advanced Head and Neck Soft Tissue Sarcoma
by Qiuji Wu, Juan Wang, Shaojie Li, Jia Liu, Yanshuang Cheng, Jieying Jin and Yahua Zhong
J. Clin. Med. 2023, 12(9), 3099; https://doi.org/10.3390/jcm12093099 - 24 Apr 2023
Viewed by 1420
Abstract
Background: Head and neck soft-tissue sarcomas are rare but aggressive malignancies. Definitive radiotherapy might be an alternative treatment choice in patients unfit for surgery with preservation of organ function and facial morphology. Whether definitive radiotherapy is comparable with surgery has not been fully [...] Read more.
Background: Head and neck soft-tissue sarcomas are rare but aggressive malignancies. Definitive radiotherapy might be an alternative treatment choice in patients unfit for surgery with preservation of organ function and facial morphology. Whether definitive radiotherapy is comparable with surgery has not been fully demonstrated. In this study, we compared the prognosis of patients with radiotherapy-based treatment and with surgery-based treatment. Methods: From May 2014 to February 2021, patients with locally advanced head and neck soft-tissue sarcoma treated with either definitive radiotherapy-based treatment or radical surgery-based treatment were retrospectively enrolled. Clinical outcomes including tumor response, patients’ survival and acute treatment-related toxicities were evaluated. Kaplan–Meier curves with log-rank test were used to compare survival data. Cox regression analysis was used to explore prognostic factors. Results: A total of 24 patients (12 males and 12 females, 3 to 61 years old) were eligible for analysis. The median follow-up time was 49 (range: 6–96) months. In 16 patients receiving definitive radiotherapy-based treatment, 6 reached complete response. The survival curve showed that there was no statistically significant difference in overall survival (OS), distant metastasis-free survival (DMFS), loco-regional relapse-free survival (LRRFS) and progression-free survival (PFS) between the two groups of patients (p = 0.35, p = 0.24, p = 0.48, p = 0.1, respectively). COX regression analysis showed that older age was associated with poor DMFS. There was no significant difference in grade 3–4 toxicities between the two groups. Conclusions: In cases of contradictions to surgery, refusal to surgery or failure to complete resection, chemoradiotherapy might be an alternative treatment option. Full article
(This article belongs to the Special Issue Targeted Treatment of Oral and Maxillofacial Diseases)
►▼ Show Figures

Graphical abstract

12 pages, 12717 KiB  
Article
PFC@O2 Targets HIF-1α to Reverse the Immunosuppressive TME in OSCC
by Zhou Lan, Ke-Long Zou, Hao Cui, Hao Chen, Yu-Yue Zhao and Guang-Tao Yu
J. Clin. Med. 2023, 12(2), 560; https://doi.org/10.3390/jcm12020560 - 10 Jan 2023
Cited by 3 | Viewed by 1743
Abstract
As a typical hallmark of solid tumors, hypoxia affects the effects of tumor radiotherapy, chemotherapy, and photodynamic therapy. Therefore, targeting the hypoxic tumor microenvironment (TME) is a promising treatment strategy for cancer therapy. Here, we prepared an Albumin Human Serum (HSA)-coated perfluorocarbon (PFC) [...] Read more.
As a typical hallmark of solid tumors, hypoxia affects the effects of tumor radiotherapy, chemotherapy, and photodynamic therapy. Therefore, targeting the hypoxic tumor microenvironment (TME) is a promising treatment strategy for cancer therapy. Here, we prepared an Albumin Human Serum (HSA)-coated perfluorocarbon (PFC) carrying oxygen (PFC@O2) to minimize OSCC hypoxia. The results showed that PFC@O2 significantly downregulated the expression of HIF-1α and the number of M2-like macrophages in vitro. Furthermore, PFC@O2 effectively inhibited the growth of oral squamous cell carcinoma (OSCC) and reduced the proportion of negative immunoregulatory cells, including myeloid-derived suppressor cells (MDSCs) and M2-like macrophages of TME in a 4-nitroquinoline N-oxide (4NQO)-induced mouse model. Conversely, the infiltration of CD4+ and CD8+ T cells was significantly increased in TME, suggesting that the anti-tumor immune response was enhanced. However, we also found that hypoxia-relative genes expression was positively correlated with CD68+/CD163+ TAMs in human tissue specimens. In summary, PFC@O2 could effectively inhibit the progression of OSCC by alleviating hypoxia, which provides a practical basis for gas therapy and gas synergistic therapy for OSCC. Full article
(This article belongs to the Special Issue Targeted Treatment of Oral and Maxillofacial Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 1339 KiB  
Review
Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma
by Han-Qi Wang, Ruxing Fu, Qi-Wen Man, Guang Yang, Bing Liu and Lin-Lin Bu
J. Clin. Med. 2023, 12(6), 2173; https://doi.org/10.3390/jcm12062173 - 10 Mar 2023
Cited by 6 | Viewed by 2426
Abstract
Surgery with the assistance of conventional radiotherapy, chemotherapy and immunotherapy is the basis for head and neck squamous cell carcinoma (HNSCC) treatment. However, with these treatment modalities, the recurrence and metastasis of tumors remain at a high level. Increasingly, the evidence indicates an [...] Read more.
Surgery with the assistance of conventional radiotherapy, chemotherapy and immunotherapy is the basis for head and neck squamous cell carcinoma (HNSCC) treatment. However, with these treatment modalities, the recurrence and metastasis of tumors remain at a high level. Increasingly, the evidence indicates an excellent anti-tumor effect of chimeric antigen receptor T (CAR-T) cells in hematological malignancy treatment, and this novel immunotherapy has attracted researchers’ attention in HNSCC treatment. Although several clinical trials have been conducted, the weak anti-tumor effect and the side effects of CAR-T cell therapy against HNSCC are barriers to clinical translation. The limited choices of targeting proteins, the barriers of CAR-T cell infiltration into targeted tumors and short survival time in vivo should be solved. In this review, we introduce barriers of CAR-T cell therapy in HNSCC. The limitations and current promising strategies to overcome barriers in solid tumors, as well as the applications for HNSCC treatment, are covered. The perspectives of CAR-T cell therapy in future HNSCC treatment are also discussed. Full article
(This article belongs to the Special Issue Targeted Treatment of Oral and Maxillofacial Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop